We assessed retention and predictors of attrition (recorded death or loss to follow-up) in antiretroviral treatment (ART) clinics in Tanzania, Uganda and Zambia.
We conducted a retrospective cohort study among adults (≥18 years) starting ART during 2003–2010. We purposefully selected six health facilities per country and randomly selected 250 patients from each facility. Patients who visited clinics at least once during the 90 days before data abstraction were defined as retained. Data on individual and programme level risk factors for attrition were obtained through chart review and clinic manager interviews. Kaplan–Meier curves for retention across sites were created. Predictors of attrition were assessed using a multivariable Cox-proportional hazards model, adjusted for site-level clustering.
From 17 facilities, 4147 patients were included. Retention ranged from 52.0% to 96.2% at 1 year to 25.8%–90.4% at 4 years. Multivariable analysis of ART initiation characteristics found the following independent risk factors for attrition: younger age [adjusted hazard ratio (aHR) and 95% confidence interval (95%CI) = 1.30 (1.14–1.47)], WHO stage 4 ([aHR (95% CI): 1.56 (1.29–1.88)], >10% bodyweight loss [aHR (95%CI) = 1.17 (1.00–1.38)], poor functional status [ambulatory aHR (95%CI) = 1.29 (1.09–1.54); bedridden aHR1.54 (1.15–2.07)], and increasing years of clinic operation prior to ART initiation in government facilities [aHR (95%CI) = 1.17 (1.10–1.23)]. Patients with higher CD4 cell count were less likely to experience attrition [aHR (95%CI) = 0.88 (0.78–1.00)] for every log (tenfold) increase. Sites offering community ART dispensing [aHR (95% CI) = 0.55 (0.30–1.01) for women; 0.40 (0.21–0.75) for men] had significantly less attrition.
Patient retention to an individual programme worsened over time especially among males, younger persons and those with poor clinical indicators. Community ART drug dispensing programmes could improve retention.
Below: Kaplan-Meier estimates by site in Tanzania, Uganda and Zambia
Below: Kaplan-Meier estimates by Community-Based Distribution (CBD) of ARVs in Tanzania, Uganda and Zambia
Full article at: http://goo.gl/f62sCn
By: Olivier Koole,1,2 Sharon Tsui,3,4 Fred Wabwire-Mangen,5 Gideon Kwesigabo,6 Joris Menten,2 Modest Mulenga,7Andrew Auld,8 Simon Agolory,8 Ya Diul Mukadi,3 Robert Colebunders,2,9 David R. Bangsberg,10,11 Eric van Praag,3Kwasi Torpey,3 Seymour Williams,8 Jonathan Kaplan,8 Aaron Zee,8 and Julie Denison3,4
1Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
2Clinical Sciences Department, Institute of Tropical Medicine, Antwerp, Belgium
3FHI 360, Durham, NC, USA
4Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
5Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda
6Muhimbili University of Health and Allied Sciences, Dar es Salaam, United Republic of Tanzania
7Tropical Diseases Research Centre, Ndola, Zambia
8Division of Global AIDS, United States Centers for Disease Control and Prevention, Atlanta, GA, USA
9Epidemiology and Social Medicine, University of Antwerp, Antwerp, Belgium
10Massachusetts General Hospital, Boston, MA, USA
11Harvard Medical School, Boston, MA, USA
Corresponding Author Olivier Koole, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. Tel.: +265 997 680 108; Email: email@example.com
More at: https://twitter.com/hiv insight